Hypertrophic cardiomyopathy: forms and variants of the course, approaches to pharmacotherapy.

Abstract

The problem of studying hypertrophic cardiomyopathy (HCM) continues to maintain its relevance, given the prevalence of the disease (1:500), and the risk of sudden cardiac death (SCD) in people of young working age. A matter of great interest are the issues of finding additional clinical, instrumental and genetic markers, environmental factors that can influence the formation of clinical variants of the course of hypertrophic cardiomyopathy, the risk of SCD and prognosis in HCM. We need a systematic approach to the formation of different forms and variants with HCM to develop tactics of treatment of patients and the formulation of risk factors for SCD.